Fortuna Mining Corp. Common Shares vs Oruka Therapeutics Inc. Common Stock — how do they compare? Fortuna Mining Corp. Common Shares trades at $10.42 (market cap $3.12B), while Oruka Therapeutics Inc. Common Stock trades at $75.2 (market cap $5.18B). The key difference: Oruka Therapeutics Inc. Common Stock is the larger of the two by market cap, and Oruka Therapeutics Inc. Common Stock is trading nearer its 52-week high, Fortuna Mining Corp. Common Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Fortuna Mining Corp. Common Shares for 6 Days and Oruka Therapeutics Inc. Common Stock for 0 Days on average.
| FSM | ORKA | |
|---|---|---|
Market Cap | $3.12B | $5.18B |
Volume | 2,648,950 | 490,798 |
Sector | Basic Materials | Health |
52-Week High | $13.66 | $113.08 |
52-Week Low | $7.84 | $26.19 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $2.74B | $4.31B |
Signals from Pluang's Aura AI — not financial advice
Fortuna Mining (FSM) trades at $10.58, down 1.67% on the day, amid a bearish technical signal. The company reported strong 2025 results with $947M revenue and $287M net income, but recent quarters have missed EPS expectations. Analyst consensus is bullish with 4 buy ratings, while technical indicators show mixed signals with a bearish moving average trend but neutral oscillators.
FSM presents a value opportunity with low P/E of 8.89 and robust profitability margins, but faces risks from production volatility and execution of growth projects. The stock's near-term performance hinges on Q3 2026 earnings and progress toward its 500,000-ounce gold production target by 2028.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Fortuna Mining is a Canadian precious-metals mining company with operations in Latin America and West Africa. It produces gold and silver and conducts exploration activities in several countries.
Read more on FSM →Oruka Therapeutics, Inc. is a clinical-stage biotechnology company developing extended half-life monoclonal antibodies for plaque psoriasis, psoriatic arthritis, and related dermatologic conditions, with lead candidates ORKA-001 and ORKA-002 in clinical trials.
Read more on ORKA →